EFTA00964821.pdf

From: Steven Victor MD <I To: Subject: Fwd: Maxim Group: Regenerative Cell Therapy: Autologous versus allogeneic is the wrong question? It's pre-clinical, manufacturing, and clinical data that drive safety Date: Mon, 08 Jul 2013 12:12:08 +0000 Attachments: Cell_Therapy_Industry_7.8.13.pdf; image001.png Steven Victor MD IntelliCell BioSciences Chairman/CEO Original Message— From: Steven Victor To: admin Sent: Mon, Jul 8, 2013 8:10 am Subject: FW: Maxim Group: Regenerative Cell Therapy: Autologous versus allogeneic is the wrong question? It's pre-clinical, manufacturing, and clinical data that drive safety Steven Victor MD Chairman Intellicell Biosciences Inc From: admin SS> Date: Monday, July 8, 2013 8:05 AM To: admin Subject: FW: Maxim Group: Regenerative Cell Therapy: Autologous versus allogeneic is the wrong question? It's pre-clinical, manufacturing, and clinical data that drive safety Steven Victor MD Chairman Intellicell Biosciences Inc EFTA00964821 From: Jason Kolbert <jasonkolbert&ptonline.net> Date: Monday, July 8, 2013 7:43 AM To: admin Subject: Maxim Group: Regenerative Cell Therapy: Autologous versus allogeneic is the wrong question? It's pre-clinical, manufacturing, and clinical data that drive safety EFTA00964822  d:[email protected] This message is intended only for use by the intended party and may contain information that is privileged and/or confidential. If you are not the intended recipient, then any review, dissemination, replication or distribution of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately and delete this message and all attachments. Electronic communications routed to any employee of Maxim Group LLC ('Maxim') are for business purposes only. While messages are confidential, authorized management, legal and compliance personnel may review electronic messages. Electronic messages are also retained and would be provided upon request to an authorized regulatory body. EFTA00964823 Do not use email to request, authorize or effect the purchase or sale of any security, to send fund transfer instructions or to effect any other transactions. Maxim does not accept responsibility for transmission via electronic means of trade orders. No guarantee can be made by Maxim of timely execution of any trade order transmitted via electronic means. The views expressed herein may not represent the opinions of the Maxim's Research Department. Maxim does not undertake to update information herein or to notify the recipients if underlying views have changed. A copy of the most recent Maxim research report is available upon request. Information included in this email does not constitute a trade confirmation or an offer or solicitation of an offer to buy/sell securities. Oast performance is not indicative of future returns. If any third-party research report (i.e. non-Maxim research report) is attached to this email message, please go to: for important third-party research disclosures relating to such research report. For any communication concerning standardized options, please see the "Characteristics and Risks of Standardized Options" document: Any attachment(s) to this electronic communication that was not prepared by Maxim has been unaltered, and is in its original form. Any recommendation, opinion, or advice regarding securities or markets contained in any documentation that was not prepared by Maxim does not necessarily reflect the views of Maxim, and Maxim does not verify any information included in such material. Lastly, Maxim and/or its employees or affiliates may have an interest in, or from time to time trade or make markets in the securities (and/or related derivatives) of the issues discussed in any attachment annexed hereto. EFTA00964824